CompletedPhase 3

Evaluate the Efficacy and Safety of MEDITOXIN in Treatment of Primary Axillary Hyperhidrosis

South Korea220 participantsStarted 2018-08-03

Plain-language summary

This study is intented to evaluate the efficacy and safety of MEDITOXIN compared to placebo in treatment of primary axillary hyperhidrosis.

Who can participate

Age range20 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * adult patients aged from 20 to 65, with persistent bilateral primary axillary hyperhidrosis Exclusion Criteria: * those who have secondary hyperhidrosis * those who have systemic neuromuscular junction disorders * women who are pregnant or lactating

What they're measuring

the proportion of treatment responder

Timeframe: 4 weeks after the injection

Trial details

NCT IDNCT03760198

SponsorMedy-Tox

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2019-07-03

View on ClinicalTrials.gov More Hyperhidrosis Primary Focal Axilla trials